Biocon Biologics inks out-licensing agreement with Yoshindo Inc

​​​Under the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab -- developed and manufactured by Biocon Biologics -- for an addressable market opportunity of USD 700 million, Biocon Biologics said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZIdzyOg
via IFTTT